Back to search results

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Abroad (travel likely)RecruitingPHASE3

Conditions

Glioblastoma · Glioblastoma Multiforme · Glioma, Malignant · GBM · Brain Cancer · Glioblastoma, IDH-wildtype · Glioblastoma Multiforme, Adult

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Lenox Hill Brain Tumor Center, New York, New York, United States

    Contact: Study coordinator (John Boockvar, MD) · jboockvar@northwell.edu · 212-434-3900
    Contact: Study coordinator (Tamika Wong, MPH) · twong4@northwell.edu · 212-434-4836
    Contact: Principal Investigator (John Boockvar, MD)
    David Langer, MD (Sub-investigator)
    Rafael Ortiz, MD (Sub-investigator)
    Tamika Wong, MPH (Sub-investigator)
    Olivia Albers, NP (Sub-investigator)
    Amy McKewon, NP (Sub-investigator)
Study leads

  • John Boockvar, MD

    Principal Investigator

    Feinstein Institute for Medical Research/Lenox Hill Hospital

View source on ClinicalTrials.gov(opens in a new tab)